5-bromo-2-deoxyuridine (BrdU) is a pyrimidine analog. It gets incorporated into the newly synthesized DNA of proliferating cells in place of thymidine. The BrdU Cell Proliferation Assay Kit detects incorporated BrdU using a mouse anti-BrdU antibody. An anti-mouse HRP-linked secondary antibody is used to detect the anti-BrdU antibody bound to BrdU, which is followed by addition of TMB (a HRP substrate). The extent of color development is proportional to the quantity of BrdU incorporated into the cells and can be used directly as an indicator of cell proliferation. Compared to other cell proliferation assays, this kit detects only the proliferating cells and not the seeded cells. This highly sensitive, non-radioactive kit detects as few as 50-100 proliferating cells.
Detection method: Absorbance at 450 nm
Applications: Detection and quantification of cell proliferation induced by growth factors, cytokines, mitogens, and nutrients. Analysis of cytotoxic and cytostatic compounds such as anticancer drugs, toxic agents and other pharmaceuticals. Determination of the inhibitory or stimulatory effects of various compounds on cell proliferation.
Assay Kit (Colorimetric)
Read Publications using NBP2-54888 in the following applications:
Be the first to review our BrdU Cell Proliferation Assay Kit (Colorimetric) and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.